TLPH
Talphera, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.20
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0K | 28.0K | — | 651.0K | — |
| Cost of Revenue | — | — | 6.7M | 5.5M | 1.6M |
| Gross Profit | 1.0K | 28.0K | (6.7M) | (4.9M) | (1.6M) |
| Operating Expenses | |||||
| R&D Expense | 6.7M | 6.0M | 6.7M | 5.5M | 1.7M |
| SG&A Expense | 8.0M | 7.5M | — | — | 17.0M |
| General & Admin Expense | 2.2M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 1.8M | 6.4M | — |
| Total Operating Expenses | 14.7M | 13.5M | 8.5M | 12.0M | 18.7M |
| Cost and Expenses | 14.7M | 13.5M | 15.3M | 17.5M | 20.4M |
| Operating Income (EBIT) | (14.7M) | (13.5M) | (15.3M) | (16.9M) | (20.4M) |
| Non-Operating | |||||
| Interest Income | 625.0K | 436.0K | 679.0K | 6.7M | 1.5M |
| Interest Expense | — | — | 394.0K | 134.0K | 1.1M |
| Net Interest Income | 625.0K | 436.0K | 285.0K | 6.6M | 386.0K |
| Other Non-Op Income/Expense | (329.0K) | (879.0K) | 2.2M | 6.6M | 79.5M |
| Non-Operating Income (excl Interest) | (619.0K) | 879.0K | (2.6M) | (6.7M) | (80.6M) |
| EBT (Pre-Tax Income) | (15.1M) | (14.4M) | (13.0M) | (10.3M) | 59.1M |
| Income Tax Expense | — | — | — | — | 13.0K |
| Bottom Line | |||||
| Net Income | (15.1M) | (14.3M) | (13.0M) | (18.4M) | 42.5M |
| Earnings from Cont. Ops | (15.1M) | (14.4M) | (13.0M) | (10.3M) | 59.1M |
| Earnings from Discont. Ops | — | 73.0K | — | (8.1M) | (11.4M) |
| Bottom Line Net Income | (15.1M) | (14.3M) | (13.0M) | (10.3M) | 42.3M |
| Per Share | |||||
| Basic EPS | ($0.32) | ($0.34) | ($0.50) | ($1.29) | $5.73 |
| Diluted EPS | ($0.32) | ($0.34) | ($0.50) | ($1.29) | $5.72 |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.05 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 75.5M | 42.4M | 25.8M | 14.3M | 7.4M |
| Diluted Shares Outstanding | 75.5M | 42.4M | 25.8M | 14.3M | 7.4M |
| Profitability Metrics | |||||
| EBITDA | (14.1M) | (14.4M) | (12.5M) | (10.1M) | 61.9M |
| D&A | — | — | 96.0K | 96.0K | 1.6M |
| EBIT | (14.1M) | (14.4M) | (12.6M) | (10.2M) | 60.3M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026